A Phase I Open Label Followed by a Phase II Randomized, Controlled Study to Assess the Efficacy and Safety of ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic
Latest Information Update: 03 May 2024
At a glance
- Drugs Ibrilatazar (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Adenocarcinoma; Carcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms PanC-ASAP
- Sponsors Ability Pharmaceuticals
Most Recent Events
- 15 Mar 2024 Status changed from recruiting to completed.
- 13 Mar 2024 Efficacy results are expected by year-end.
- 28 Mar 2023 Planned End Date changed from 1 Mar 2025 to 1 Sep 2028.